Elan has given an update on the use of its multiple sclerosis drug Tysabri. The Athlone-based firm says that as at the end of last month, about 26,000 patients were on commercial and clinical therapy worldwide.
Most importantly it says there has been no more cases of the potentially fatal PLM disease since the drug was relaunched in the July 2006.
Elan has a goal of treating 100,000 patients worldwide with Tysabri by 2010.
The data was presented at the 60th annual meeting of the American Academy of Neurology.
'Positive outcomes for patients continue to support Tysabri's strength as a valuable treatment for multiple sclerosis patients in more than 30 countries around the world,' commented Gordon Francis, Senior Vice President of Global Clinical Development at Elan.
'We are also excited that patients with Crohn's Disease are now beginning to receive Tysabri treatment in the US,' he added.
Elan shares closed €1.60 higher at €14.95 in Dublin.
